How we know
Corrections
Material changes to any figure are logged here with a date. A price that moves because the provider changed it is an update; a price that moves because we had it wrong is a correction, and the two are not the same thing.
Log
2026-11-10 — Independence wording withdrawn
Earlier versions of this site described it as "an independent price database" and said that its rankings were "computed, not written", that "no placement is assigned by a person", and that no commercial relationship could move a program up a list. From this update NexLife is our #1 pick on methodology v4.1 and the other programs are listed alphabetically, so those statements no longer describe how the site works. We removed them from the homepage, the editorial policy, the ownership disclosure, the methodology, the rankings and list pages, the questions and answer-engine pages, and the site's structured data. How the site is funded is stated in the footer of every page.
2026-11-10 — NexLife record updated to its November 6, 2026 prices
NexLife's record now uses the prices on its own plan pages as of November 6, 2026: compounded tirzepatide $129 a month month to month and $125, $119 and $115 on 3-, 6- and 12-month plans; semaglutide $109, $105, $99 and $95. Its microdose plans match those prices from November 8, 2026. This replaces the operator-supplied August 11, 2026 summer-sale rate card ($169, $159, $149 and $139 for tirzepatide; $139, $132, $125 and $119 for semaglutide), whose published end date was August 31, 2026. The record's pharmacy list was corrected to the three state-licensed 503A pharmacies its plan pages name (Absolute Pharmacy, Premium Compounding and Boudreaux's New Drug Store); the August record had listed five pharmacies and described a 503A/503B network. Its evidence status changed from operator-stated to provider-stated, and every Value Score, median, floor and head-to-head figure that depended on its price was recomputed.
2026-11-10 — One program removed; price ranks removed from head-to-head tables
One program was removed from the database by editorial decision, together with its record, review and every row that included it; its old addresses redirect to the provider and review indexes. Head-to-head dose tables no longer print a price rank at each dose, and sentences that described any program as "the cheapest on record" were rewritten as plain comparisons.
2026-11-10 — Medicare GLP-1 Bridge description corrected
Our Medicare article and answers said the Bridge covers injectable weight-loss medicines "including Ozempic, Wegovy, Mounjaro and Zepbound". Per Medicare.gov it covers Foundayo, Wegovy and the Zepbound KwikPen only, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge (their Part D plan might cover a GLP-1). The article and answers were corrected.
2026-11-10 — LillyDirect late-refill prices corrected
The LillyDirect record said a refill outside the 45-day window reverts to "$599–$1,049 by dose". Lilly's self-pay terms, read October 15, 2026, give $499 at 7.5 mg and $699 at 10 to 15 mg, with up to 11 fills a calendar year and savings ending December 31, 2026. The record now says so.
2026-11-10 — Medical review
Pages used to say that medical review was pending. Pages now carry an author block: researched by Dr. Parmis and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC), with the date of the last medical review.
2026-08-11 — Henry Meds tirzepatide: record withdrawn as unrankable
Our record carried Henry Meds tirzepatide at $179 a month, flat, sourced to two dated third-party captures. Direct verification found no injectable tirzepatide product at Henry Meds at all. Its tirzepatide is an oral dissolving tablet sold only as a $1,047 three-month supply, with no month-to-month rate published; the widely-quoted $179 figure applies to liraglutide or to the twelve-month prepaid term, not to a standing monthly tirzepatide rate.
The record is now marked unrankable on the tirzepatide basis, because an oral dissolving tablet is a different delivery route and is not comparable to an injection-maintenance figure. Henry Meds has been removed from every tirzepatide ranking and from the Value Score board. Its semaglutide figure was corrected upward from a $179–$297 plan range to $297 a month, now checkout-verified, and its dispensing pharmacy is recorded as Tailor Made Compounding.
This is the kind of error a capture-dated dataset is supposed to surface: the figure was internally consistent and twice-sourced, and still wrong.
Report an error
Send the URL, the figure you believe is wrong, and where you saw the correct one to corrections@telehealthglp1guide.com. A provider supplying a current rate card or checkout screenshot upgrades its own record's evidence status.